Workflow
国药现代:全资子公司国药威奇达通过药品GMP符合性检查

Core Viewpoint - The announcement indicates that the wholly-owned subsidiary of China National Pharmaceutical Group, Weichida Pharmaceutical Co., Ltd., has successfully passed the GMP compliance inspection for its production lines, which is a significant milestone for the company as it prepares for the market launch of its product, Acarbose [1] Group 1 - Weichida Pharmaceutical received a GMP compliance inspection notice for its production lines in workshop 108 and the comprehensive raw material drug workshop [1] - The inspection covered the raw material drug Acarbose, marking the first GMP compliance check prior to the product's market launch [1] - The production lines in question are renovated old factory workshops, with a total construction investment of approximately 22.76 million yuan [1] Group 2 - The current production capacity for Acarbose is designed at 12 tons per year [1]